Crohn’s & Colitis Foundation Perspectives

ReachMD
  • 4.5 (13)
  • SCIENCE

As research in inflammatory bowel diseases (IBD) advances, the landscape is rapidly evolving; requiring reinforcement of the most important and clinically relevant data. This educational series will provide the latest information on research, treatments, and management of IBD with a focus on the most pressing and relevant topics identified by the Crohn’s & Colitis Foundation's National Scientific Advisory Committee on Crohn’s Disease and Ulcerative Colitis. With 1.6 million Americans living with IBD, which includes Crohn’s disease and ulcerative colitis, and approximately 70,000 new cases diagnosed annually, the Crohn’s & Colitis Foundation is dedicated to developing and cultivating IBD healthcare providers through continued education and creation of valuable resources that directly impact the standard-of-care and everyday clinical practices in IBD. The Crohn’s & Colitis Foundation is the only national organization dedicated to driving efforts in IBD research, education and support for patients, caregivers, and professionals.  The Crohn’s & Colitis Foundation is building initiatives to address high priority areas, and developing the tools, including this educational series, to educate healthcare professionals and meet patients’ needs.   In Collaboration with

  1. 06/30/2022

    Crohn’s & Colitis Congress 2022: A Look at Diet & Nutrition Therapies

    Host: Jennifer Caudle, DO Guest: Maitreyi Raman , MD, MSc, FRCPC Diet and nutrition is known to play a large role in the onset and treatment of IBD. So what were some of the trending sessions focusing on diet and nutrition at the 2022 Crohn’s & Colitis Congress? Join Dr. Jennifer Caudle as she speaks with Dr. Maitreyi Raman to explore the latest research advancements in diet therapies.

  2. 04/21/2022

    Crohn's & Colitis Congress 2022: Looking Back & Looking Ahead with the 2023 Chair

    Host: Charles Turck, PharmD, BCPS, BCCCP Guest: Peter D. Higgins, MD, PhD What were some of the key takeaways from the 2022 Crohn's & Colitis Congress, and what's in store for next year’s conference? Hear from the incoming 2023 Congress Chair Dr. Peter D. Higgins.

  3. 04/08/2022

    Crohn's & Colitis Congress 2022: Combating Challenges for Pediatric Patients

    Host: Jennifer Caudle, DO Guest: Ashish S. Patel, MD Treating IBD in our pediatric patients can be challenging, which is why creating a strong partnership between care teams and patients’ families is key. Fortunately, that was a central focus of the 2022 Crohn's & Colitis Congress, so to catch the latest updates and strategies for improving IBD care for pediatric patients, tune in to hear Dr. Jennifer Caudle speak with Dr. Ashish Patel.

  4. 04/01/2022

    Crohn's & Colitis Congress 2022: Improving Moderate Ulcerative Colitis Care

    Host: Jennifer Caudle, DO Guest: Alan C. Moss, MD, FACG, FEBG, AGAF, FRCPI When patients with moderate ulcerative colitis fail first-line therapy, it's important to know what to do next. And speaking with your patients about their risks and preferences is key. Join us as Dr. Alan Moss shares highlights from his presentation at the 2022 Crohn's & Colitis Congress on treatment considerations for patients with moderate ulcerative colitis.

  5. 12/10/2021

    Exploring the DINE-CD Study & the Importance of Diet for IBD Patients

    Host: Peter Buch, MD, FACG, AGAF, FACP Guest: Caren Heller, MD, MBA For patients living with IBD, paying special attention to their nutrition is paramount. So which is more effective for IBD patients with mild-to-moderate symptoms: a Mediterranean style diet or the Special Carbohydrate diet? That’s what the Diets to Induce Remission in Crohn's Disease (DINE-CD) study sought to find out, and now the results are in. Join Dr. Peter Buch as he explores the study's key findings with Dr. Caren Heller, Chief Scientific Officer at the Crohn's and Colitis Foundation.

  6. 06/08/2021

    Endoscopic & Histological Assessment, Correlation, & Relapse in Clinically Quiescent Ulcerative Colitis

    Guest: Jordan E. Axelrad, MD, MPH Endoscopic and Histological Assessment, Correlation, and Relapse in Clinically Quiescent Ulcerative Colitis (MARQUEE) Mark T Osterman, Frank I Scott, Franz F Fogt, Erin D Gilroy, Susan Parrott, Joseph Galanko, Raymond Cross, Alan Moss, Hans H Herfarth, Peter D R Higgins Abstract Objective: It is difficult to predict relapse in quiescent ulcerative colitis (UC), but newer endoscopic and histological indices could improve this. This study aimed to determine in UC patients in clinical remission (1) the prevalence of active endoscopic and histological disease; (2) the correlation between endoscopic and histological scores; and (3) the predictive power of these scores for clinical relapse. Design: This multicenter prospective cohort study conducted by the Crohn's and Colitis Foundation Clinical Research Alliance included 100 adults with UC in clinical remission undergoing surveillance colonoscopy for dysplasia. Endoscopic activity was assessed using the Mayo endoscopic score (MES), ulcerative colitis endoscopic index of severity (UCEIS), and ulcerative colitis colonoscopic index of severity (UCCIS). Histology was assessed with the Riley index subcomponents, total Riley score, and basal plasmacytosis. Results: Only …

  7. 04/08/2021

    Keeping CALM in Crohn’s Disease: An Exploration of Biomarker Cutoffs & Endoscopic Outcomes

    Guest: Xiaohong Wang, MD, PhD Association of Biomarker Cutoffs and Endoscopic Outcomes in Crohn's Disease: A Post Hoc Analysis From the CALM Study Walter Reinisch, Remo Panaccione, Peter Bossuyt, Filip Baert, Alessandro Armuzzi, Xavier Hébuterne, Simon Travis, Silvio Danese, William J Sandborn, Stefan Schreiber, Sofie Berg, Qian Zhou, Kristina Kligys, Ezequiel Neimark, Ahmed A Suleiman, Geert D'Haens, Jean-Frederic Colombel Background: CALM was a randomized phase 3 trial in patients with Crohn's disease (CD) that demonstrated improved endoscopic outcomes when treatment was escalated based on cutoffs for inflammatory biomarkers, fecal calprotectin (FC), C-reactive protein (CRP), and CD Activity Index (CDAI) remission vs CDAI response alone. The purpose of this post hoc analysis of CALM was to identify drivers of treatment escalation and evaluate the association between biomarker cutoff concentrations and endoscopic end points. Methods: The proportion of patients achieving CD Endoscopic Index of Severity (CDEIS) 4 and no deep ulcers 48 weeks after randomization was evaluated according to CRP 5 mg/L or ≥5 mg/L and FC 250 μg/g or ≥250 μg/g. Subgroup analyses were performed according to disease location, and sensitivity analyses were conducted in patients with elevated CRP and/or FC at baseline. The association between endoscopic end points and biomarker cutoffs was performed using …

  8. 04/03/2021

    Crohn’s & Colitis Congress 2021: Getting a Holistic View of IBD Diet Disparities & Well-Being

    Guest: Tina Aswani Omprakash Wellness includes many different aspects, but what about mental health and the stressors of life that affect IBD patients? Joining Dr. Charles Turck to share key takeaways from a session at the 2021 Crohn’s and Colitis Congress called “Holistic View of IBD Diet Disparities and Well-Being” is Tina Aswani Omprakash, patient advocate and co-moderator of the session.

See All (96)

Ratings & Reviews

4.5
out of 5
13 Ratings

About

As research in inflammatory bowel diseases (IBD) advances, the landscape is rapidly evolving; requiring reinforcement of the most important and clinically relevant data. This educational series will provide the latest information on research, treatments, and management of IBD with a focus on the most pressing and relevant topics identified by the Crohn’s & Colitis Foundation's National Scientific Advisory Committee on Crohn’s Disease and Ulcerative Colitis. With 1.6 million Americans living with IBD, which includes Crohn’s disease and ulcerative colitis, and approximately 70,000 new cases diagnosed annually, the Crohn’s & Colitis Foundation is dedicated to developing and cultivating IBD healthcare providers through continued education and creation of valuable resources that directly impact the standard-of-care and everyday clinical practices in IBD. The Crohn’s & Colitis Foundation is the only national organization dedicated to driving efforts in IBD research, education and support for patients, caregivers, and professionals.  The Crohn’s & Colitis Foundation is building initiatives to address high priority areas, and developing the tools, including this educational series, to educate healthcare professionals and meet patients’ needs.   In Collaboration with

Information